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Juliet N. Barker,1 Vanderson Rocha,2 Andromachi Scaradavou3In contrast to the very high transplant-related mortality (TRM) associated with the early experience of cord
blood (CB) transplantation (CBT), recent transplant series have been associated with comparable survival to
that of human leucocyte antigen (HLA)-matched unrelated donor transplantation in children with similarly
promising results in adults. Consequently, the use of CB as an alternative stem cell source and the global in-
ventory of units in public banks are rapidly increasing although challenges remain. This review will address
efforts to optimize CBT from 3 different perspectives: that of the transplant center, the CBT registry, and
the CB bank.
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Allogeneic hematopoietic stem cell (HSC) trans-
plantation is limited by a lack of suitable donors.
Cord blood (CB) has the advantage of ready availabil-
ity and a reduced HLA match requirement [1-4].
Recent data suggests that CB therefore extends trans-
plant access to racial and ethnic minorities (Table 1).
In addition to the less than expected incidence of
graft-versus-host disease (GVHD) [1-4], the GVHD
after cord blood transplantation (CBT) may be easier
to treat [5]. However, CBT can have major limitations
primarily related to engraftment [1-4]. Therefore, to
fulfill the promise of CBT it is important to consider
all strategies by which CBT outcome can be opti-
mized. This review will address this challenge from 3
vantage points: that of the transplant center (TC),
the transplant registry, and the CB bank.ATC PERSPECTIVE
When to Consider CB as a HSC Source
The first step to optimize CBT outcome is to con-
sider CB as a potential alternative as soon as the patient1Memorial Sloan-Kettering Cancer Center, New York,
York; 2Hospital Saint Louis and Eurocord-EBMT Regis-
aris, France; and 3National Cord Blood Program, New
Blood Center, New York, NewYork.
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6/j.bbmt.2008.10.020is an allogeneic transplant candidate but does not have
any suitable sibling donors and before the disease is far
advanced. The TC must establish an unrelated donor
(URD) HSC algorithm and decide how much HLA
mismatch will be tolerated in HLA-A, B, C, DRB1,
and DQ allele-typed URD before an alternate HSC
source is sought. Prolonged URD searches can com-
promise the patient’s care. Therefore, the TC should
review the patient’s HLA typing, the preliminary
URD search, and the patient’s ancestry, and assess
the likelihood that a suitably matched URDwill be se-
cured in the required time period. For patients with
less common HLA typing, especially non-Europeans,
a simultaneous search for CB should be performed.The CB Search
The CB search continues to be a challenge with no
centralized search mechanism to access all units in the
global inventory (Figure 1). Standardizing banking
standards including the information needed by TCs
should be a priority. In the meantime, to assist search
coordinators the TC should establish: (1) what banks
will be searched, (2) a unit selection algorithm that de-
fines a satisfactory single unit, (3) criteria for a double-
unit graft, and 4) whether backup units will be reserved
in the event there are problems with shipping/thaw or
graft failure. Factors to be considered in unit selection
are summarized in Table 2.The Preparative Regimen and Immune
Suppression (IS)
Although the ideal conditioning for CBT is not de-
fined, it is likely changes in conditioning and IS can
improve CBT outcome. For example, consider the
Table 1. Ancestry of 52 CBT Recipients at Memorial Sloan-
Kettering Cancer Center 10/05-5/08
Patient Ancestry N of CBT Recipients
Northwest Europe 4 (8%)
Eastern Europe 6 (12%)
Southern Europe 8 (15%)
European mix 8 (15%)
Asian 7 (13%)
African 10 (19%)
Hispanic/Latino 8 (15%)
Middle Eastern 1 (2%)
Total 52
Biol Blood Marrow Transplant 15:154-161, 2009 155Optimizing Unrelated Donor Cord Blood Transplantationimproved survival reported with myeloablative dou-
ble-unit CBT [6]. The single-unit historic controls
were transplanted using cyclophosphamide (Cy) and
total-body irradiation (TBI) with antithymocyte glob-
ulin (ATG) and cyclosporine-A (CSA)/methylprednis-
olone (MP) [4]. Although the double-unit transplants
were also performed with Cy/TBI 1 CSA, the ATG
and MP were substituted with fludarabine (Flu) and
mycophenolate mofetil (MMF), possibly accounting
for some of the improved outcome. This question is
therefore being investigated in the Clinical Trials Net-
work single- versus double-unit randomized trial in
children utilizing Cy/Flu/TBI 1 CSA/MMF.
For patients who cannot tolerate high-dose condi-
tioning reduced-intensity (RI) or nonmyeloablative
(NMA) conditioning in patients with high-risk hema-
tologic malignancies has been associated with an over-
all survival (OS) of 45% and progression-free survival
(PFS) of 38% at 3 years [7]. A major question in NMA
CBT is how to ensure engraftment in patients withoutSeoul
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Figure 1. A schema representing the relationships between current CB bank
virtue of performing a search of the National Marrow Donor Program (NMDP
spectively. The black rectangle represents the banks that can be seen by perfo
Swedcord and AsiaCORD were not listed in BMDW as of 4/08. The schema r
mechanism so that the global CB inventory can be easily accessed by transplan
Halet, NMDP (updated as of April 2008).recent exposure to combination chemotherapy or
a prior autologous transplant (Figure 2) given the addi-
tion of ATG has been associated with a high incidence
of posttransplant lymphoproliferative disease [8]. In-
vestigation of preparative regimens that include agents
that augment recipient IS without impacting the graft
should be a priority in this patient population. Further,
the efficacy of RI/NMA CBT in specific diseases
should now be the subject of Phase II studies.
Although the ideal prophylaxis against GVHD in
CBT has also not been established, CSA/MMF is rel-
atively well tolerated in patients with intact renal func-
tion. Methotrexate should be avoided because of the
risk of delayed engraftment. The use of ATG is associ-
ated with impaired immune recovery [8,9] and cortico-
steroids should likely similarly be avoided.The CB Graft
Graft failure is a major risk associated with CBT,
and from early in CBT experience it was recognized
that the total nucleated cell (TNC) dose and the in-
fused CD341 dose/kg were significant determinants
of sustained donor engraftment. Perhaps the simplest
strategy being investigated to augment engraftment
is the infusion of a double-unit graft. This approach
is as equally relevant to many children as adults, given
graft failure remains a devastating feature of many pe-
diatric series, and many larger children will only have
access to units of relatively low cell dose.
Initial investigation with myeloablative double-
unit CBT yielded a disease-free survival (DFS) of
57% [6] with updated analysis of 83 patients withCordMX
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epresents the complexity of CB searches. Creating a centralized search
t centers should be a priority. Reproduced with permission from Mary
Table 2. Major Criteria for Cord Blood Unit Selection
Criteria Comments
HLA-A, B antigen,
DRB1 allele match
Although HLA match requirement less
stringent, HLA match still a critical
determinant of TRM.
Up to 2 mismatches acceptable, although
how to trade off TNC dose and HLA
match not known.
TNC dose/kg Threshold for acceptable cell dose likely
varies according to HLA match (the more
mismatch the higher the required TNC).
Use units < 2.5  107/kg with caution.
Need to correct TNC of RBC replete
units in order to compare to TNC
of RBC depleted units.
Bank of origin Quality of units can vary from unit to
unit and bank to bank.
Speed of turnaround time, reliability of
unit information, and fees for unit testing
can vary from bank to bank.
CT from attached segment Only way to confirm unit identity.
IDMs and
hemoglobinopathy testing
Should ensure completeness of testing
so as not to slow down acquisition of
the unit. Must be completed before unit
is shipped.
HLA indicates human leucocyte antigen; TNC, total nucleated cell; RBC,
red blood cell; CT, confirmatory HLA typing; IDMs, infectious disease
markers.
156 Biol Blood Marrow Transplant 15:154-161, 2009J. N. Barker et al.high-risk hematologic malignancies showing a DFS of
54% (Professor John Wagner, personal communica-
tion). Engraftment appears improved after double-
unit CBT despite only 1 relatively low cell dose unit
engrafting, suggesting that the ‘‘losing’’ unit is facili-
tating the engraftment of the winner. Interestingly,
analysis of postthaw CD341 cell viability has sug-
gested that double-unit CBT is efficacious because it
increases the chance of receiving at least 1 unit of
high viability and thus with engraftment potential
[10]. This suggests that postthaw CD341 cell viability
could be an effective measure of unit quality and, un-
like colony-forming unit (CFU) assays, is available
on transplant day. Methods to determine unit quality
both prior to and at thaw should be a major priority.
Although the poor engraftment and high TRM as-
sociated with low TNC dose in single-unit CBT has
led to a focus on graft cell dose, unit selection is com-
plicated by HLA match, also influencing engraftmentDays Post-
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Figure 2. Association between prior chemotherapy exposure and sustained d
data.and TRM. For example, in an analysis of 989 single-
unit myeloablative CBT recipients facilitated by the
New York Blood Center (NYBC), HLA-A, B antigen,
DRB1 allele match was associated with significantly
improved engraftment, less severe acute GVHD
(aGVHD), lower TRM, and improved survival [11].
Therefore, the TC must decide how to choose be-
tween the smaller better matched versus the larger
less matched unit. The NYBC analysis suggests that
HLA match can partially compensate for lesser cell
dose with a selection algorithm of 6 of 6 units, 5 of
6s .2.5  107/kg, and 4/6s .5.0  107/kg. However,
many patients will not have access to such units, and
some with such units will still not engraft. Clearly,
more work is needed to resolve the dose versus match
trade off.
The Thaw
The albumin-dextran dilution with centrifugation
(‘‘wash’’) thaw methodology is appropriate for small
children but has been adopted for adult CBT as a mat-
ter of convention. However, a ‘‘no-wash’’ technique di-
lutes the product without centrifugation and is
advantageous for adolescents and adults in whom
even modest cell losses may be significant. This tech-
nique is faster, more efficient, reduces unit manipula-
tion, speeds time to infusion, and reduces the
potential for cell loss, and is still done in the controlled
laboratory environment. This thaw has been adopted
for patients over 20 kg at Memorial Sloan-Kettering
Cancer Center (MSKCC) and in 50 double-unit
CBT recipients has been associated with no serious in-
fusion reactions and a high level of sustained donor en-
graftment (J. Barker, unpublished data).
GVHD, Infection, and Relapse
CBT has consistently demonstrated a lower than
expected incidence of aGVHD and chronic GVHD
(cGVHD) [1-4]. However, CB can be associated with
severe GVHD, and transplant success is contingent
upon therapeutic levels of a calcineurin inhibitor in
the first months after transplant and how to transplant
patients who cannot tolerate CSA is not established.Transplant
1 28 35 42
I
Chemotherapy > 4 months prior
to UCBT or never/ no autologous
transplant (n = 14)
p = 0.03
I
onor engraftment after non-myeloablative CBT. University of Minnesota
Biol Blood Marrow Transplant 15:154-161, 2009 157Optimizing Unrelated Donor Cord Blood TransplantationThe nature of aGVHD after CBT and its response to
therapy has yet to be examined in detail. However, Ar-
ora et al. [5] found more frequent therapy responses
and a lower TRM in CBT recipients with cGVHD
compared to predominantly HLA-matched URD
BMT recipients. It is possible that some CBT recipi-
ents with GVHD may be successfully treated with
less IS than is traditionally administered as therapy af-
ter adult donor transplants. This is another field re-
quiring investigation in CBT.
Infection is a major challenge after CBT, and at
many TCs infection-related mortality is the most fre-
quent cause of CBT death, with the majority of deaths
occurring within the first 3-4 months. Although ag-
gressive supportive care to abrogate neutropenic sepsis
and prevent fungal infections with extended spectrum
azoles have led to decreased TRM, viral infections
such as cytomegalovirus (CMV) or adenovirus remain
a critical challenge in the early postengraftment period
[12]. How to augment immune recovery is a major
question. Cellular therapy approaches to the treatment
of both infection and relapse, whereas challenging
given the naı¨ve neonatal immune system may yet
show promise. In the interim, avoidance of ATG as
well as aggressive supportive care including surveil-
lance for viral reactivation is critical in early posttrans-
plant. The single best strategy to prevent relapse is to
refer the patient for transplant before disease is ad-
vanced or refractory. Measures to augment immune
reconstitution assume greater importance given im-
proved immune recovery has been associated with pro-
tection against leukemic relapse [13]. Interestingly,
preliminary data has suggested that double-unit CBT
may be associated with a reduced relapse risk [7,14].A REGISTRY PERSPECTIVE
Since the first CBT from an HLA-identical sibling
20 years ago, progress in URD CBT has been paral-
leled by the development of CB banks worldwide. To-
day, at least 350,000 CB grafts are available in moreChildren  n=2036
Adults  n=1690
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Figure 3. Unrelated CBT according to recipithan 45 banks and more than 14,000 CBT have been
performed (V. Rocha, Eurocord, CIBMTR and Asian
Pacific Registries). To evaluate CBT and foster re-
search in CB biology the European Blood andMarrow
Transplantation group (EBMT) established Eurocord
in 1995. The Eurocord registry collaborates with the
EBMT registry and Netcord banks collecting and val-
idating clinical data from European and non-Euro-
pean patients transplanted with both Netcord and
non-Netcord units. An important objective is to report
to Netcord banks outcomes data concerning their
units, a critical component of quality control. Other
objectives are to monitor trends in CB use, analyze
CBT outcomes, and assist clinicians in unit choice.Changes in the Use of CB in Recent Years
From 1988 to March 2008, 4347 CBT have been
reported to Eurocord from 415 European and non-
European TCs including 44 countries with one-third
from non-European centers. TCs have utilized related
donors (n 5 473, majority HLA-identical) for treat-
ment of malignant and nonmalignant disorders with
3835 unrelated grafts. During the last 3 years unrelated
CBT has increased to more than 500/year, and since
2004, adult CBT has overcome pediatric CBT (Euro-
cord registry data; Figure 3). Table 3 lists the URD
CBT reported to Eurocord.Risk Factor Analysis for Outcomes After
Pediatric and Adult Cord Blood Transplantation
Retrospective registry studies have demonstrated
the profound impact of cell dose (measured as TNC,
CFUs, or CD341 cells) on engraftment, TRM, and
survival [2-4,15]. More recently the prognostic impor-
tance of HLA disparity has became apparent [15]. Few
series reporting outcomes after single-unit CBT for
adults have been published with studies reporting
DFS varying from 15%-76% [16-21]. Differences in
outcomes can likely be explained by the heterogeneity
in indications and disease status, CB graft selection,
center effect, and the period of transplant. EurocordMarch 2008
*Still collecting
data
02 2004 2006 2008
ent age and year reported to Eurocord.
Table 3. Number of Unrelated CBTs Reported to the Euro-
cord Registry According to Recipient Age and Diagnosis
Diagnosis
Children #16 years
(n 5 2494)
Adults >16 years
(n 5 1727)
Acute lymphoblastic
leukemia
38% 24%
Acute myeloid leukemia 16% 31%
Secondary acute leukemia 3% 6%
Myelodysplastic syndrome 5% 9%
Chronic myeloid leukemia 2% 11%
Chronic lymphocytic
leukemia
— 1%
Hodgkin/Non-Hodgkin
Lymphoma
2% 11%
Myeloma — 2%
Solid tumors — 0.5%
Histiocytosis 4% —
Congenital and acquired BM
Failure syndromes
10% 4%
Hemoglobinopathies 0.5% —
Primary
immunodeficiencies
11% —
Metabolic diseases 8% 0.3%
Other diseases 0.5% 0.2%
BM 5 bone marrow.
158 Biol Blood Marrow Transplant 15:154-161, 2009J. N. Barker et al.has published the outcomes and risk factors after single
unit myeloablative CBT in adults (n 5 171) with he-
matologic malignancies since 1997 [20]. In summary:
(1) a higher TNC dose .2.0  107/kg and use of he-
matopoietic growth factors were independently associ-
ated with faster neutrophil recovery; DFS and relapse
were associated with advanced disease status. Two-
year DFS for patients transplanted in early, intermedi-
ate, and advanced phases of disease were 41% 6 9%,
34%6 10%, and 18%6 4%, respectively. These find-
ings mandate new approaches in adult CBT such as
double-unit grafts and RI conditioning to circumvent
the problem of low cell dose and high TRM.P < 0.0001
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Figure 4. Transplant-related mortality in 925 CBTrecipients with ma-
lignant diseases according to infused TNC Dose (107/kg) and HLA dis-
parity.Criteria for Cord Blood Unit Selection
Although infused TNC and CD341 dose are im-
portant risk factors for CBT outcome, the impact of
HLA-match and other risk factors for OS and DFS
have been controversial. Eurocord has analyzed 925
patients given a myeloablative single-unit CBT for
malignant disorders from 1994 to 2005 [15]. The me-
dian age was 11 years with 37% adults, and the median
follow-up of survivors was 28 months. Most patients
(75%) had acute leukemia (20% early phase, 42% in-
termediate phase, and 38% advanced disease). The
CB graft was HLA-matched (6 of 6) in 9%, 41% had
1 HLA mismatch, 41% 2 HLA mismatches, and 9%
had 3 or 4. The median infused TNC dose was 3.1 
107/kg, and the median infused CD341 dose was 1.4
 105/kg (n 5 667). The cumulative incidence (CI)
of day 100 neutrophil recovery was 77%, and day
180 platelet recovery was 55%. The CI of day 100
grade II-IV aGVHD was 33%, with a day 100 TRM
of 28%. At 3 years the CI of relapse and cGVHDwere 23% and 29%, respectively. At 3 years estimated
OS and DFS were 41% and 37%, respectively. In mul-
tivariate analysis increased early TRM was associated
with increased HLA disparity (P 5 .0005), TNC
dose\2  107/kg (P 5 .0002) and advanced disease
(P 5 .01), whereas for relapse increasing number of
HLA disparities (P5 .0002) decreased relapse. In mul-
tivariate analysis for OS the most important factors
were: (1) recipient CMV sero-status (P 5 .008), (2)
early disease phase (P 5 .002), (3) infused TNC .2
 107/kg (P5 .008). However, only early disease status
at CBT and infused TNC.2 107/kg (P5 .02) were
associated with better DFS in a multivariate model.
Therefore, cell dose remains 1 of the most important
risk factors associated with CBT outcome for patients
with malignancy. Eurocord does not recommend sin-
gle-unit CBT with a cryopreserved TNC dose\2.5
 107/kg or\2  107/kg at infusion. The number of
HLA disparities was not associated with OS or DFS
because although it increased early TRM (Figure 4),
in contrast to NYBC data [11], it decreased relapse
in patients with malignancy. However, because of the
risk of graft failure a CB graft should not contain
more than 3 of 6 HLA disparities. A larger series of pa-
tients is needed to establish the acceptable TNC dose
for each level of HLA mismatch, and further research
is required to establish why the Eurocord and NYBC
registries differ in their findings concerning the rela-
tionship between HLA disparity and relapse.
Outcomes Analysis of Reduced Intensity
Conditioning (RIC) andDouble-Unit CordBlood
Transplantation
Recently RIC regimens and double-unit grafts
have extended the use of CBT in adults. In a Eurocord
survey 74 adults (median 35 years) received myeloabla-
tive double-unit CBT for the treatment of acute leuke-
mia. Median follow-up was 12 months, and median
cryopreserved TNC dose was 3.5  107/kg. CI of
day 60 neutrophil recovery was 80% and 1-year OS
Biol Blood Marrow Transplant 15:154-161, 2009 159Optimizing Unrelated Donor Cord Blood Transplantationwas 45% (V. Rocha, unpublished Eurocord data).
These preliminary results show that double-unit
CBT may be helpful to circumvent low cell dose but,
longer follow-up of larger patient series is needed.
Recently, Eurocord, the French Society of Stem
Cell Transplantation, and the University of Minnesota
have analyzed outcomes after RICBTusing single units
in 176 patients (median 45 years, 16-76) with hemato-
logic malignancies: 116 acute leukemia, 36 lymphoid/
plasma cell diseases, and 24myelodysplasia (MDS)/my-
eloproliferative (MP) diseases (V. Rocha, unpublished
Eurocord data). The median follow-up was 12 months
(3-80) with 51% having advanced disease and 30% hav-
ing prior autologous transplants. Conditioning varied
according to disease and center.However, 95%received
a Flu containing regimen including 55% Flu/Cy/
TBI2Gy, 16% busulfan-containing regimen (\8 mg/
kg), and 29% other combinations, with ATG in 23%.
GVHD prophylaxis was most commonly (72%) CSA/
MMF. All received a single unit graft that was 6 of 6 in
6%, 5 of 6 in 27%, 4 of 6 in 55%, and 3 of 6 in 11%.
The median infused TNC was 2.7  107/kg. Day 60
neutrophil recovery was 78% 6 3%. In multivariate
analysis, 3 factors were independently associated with
neutrophil recovery: (1) TNC dose (\ versus .2.7 
107/kg, P 5 .02), (2) HLA-match (5-6 of 6 versus 3-4
of 6, P 5 .04), and (3) use of Flu/Cy/TBI versus other
regimens (P 5 .01). Day 100 grade II-IV aGVHD was
30%. At 1 year 30% had cGVHD and TRM was 38%.
Notably, 1-year TRM was 19% for patients given low-
dose TBI (\6 Gy) and 61% without TBI, and 40% if
low cell dose (\2.7  107/kg) compared to 21% for
higher cell dose patients, and in multivariate analysis
both low TNC dose and lack of TBI were associated
with increased TRM. Relapse at 1 year was 41% and
was associated with disease status at CBT. DFS was
41% for patients with acute leukemia, 31% if MDS/
MP diseases, and 42% for lymphoid/plasma cell dis-
eases. In a multivariate analysis advanced disease status
(P 5 .03) and conditioning other than Flu/Cy/TB I2
Gy (P5 .004) were associated with decreased DFS. Al-
though TNC dose is a critical determinant of engraft-
ment and TRM after RI CBT, the Flu/Cy/TBI2Gy
provides better engraftment, reduced TRM, and better
DFS. Despite short follow-up, these results support
the use of this regimen as a strategy for broadening
CBT to those previously excluded on the basis of age
and comorbidities. Analysis of this regimen with dou-
ble-unit grafts is underway.THE BANK’S PERSPECTIVE
Standardization of CB Freezing and CFUAssays
to Enhance the Quality of Banked CB Units
With the increasing numbers of CB collections
worldwide and the variety of processing and freezingmethodologies used by CB banks, evaluation of the
quality of the graft has become an important focus.
The National Cord Blood Program (NCBP) of the
NYBC has used automated controlled rate freezing
with the BioArchive System since 1999. These
freezers combine computer-controlled freezing with
storage, thus eliminating the need to transfer the fro-
zen CB unit to another freezer. Such a system limits
the exposure of cryopreserved units to higher temper-
atures known as transient warming events (TWE).
This is of great significance, given the NCBP has
documented that TWE impair unit viability and
CFU growth [22,23].
The Bioachive System also strictly regulates the
cooling and freezing rates for the 3 phases of the freez-
ing process (prefreeze: from initial temperature to
23C with a cooling rate of 10C/min; freeze: from
23C to 212C; and a final phase with a slower tem-
perature decline of 2C/min to 250C). Stringent
monitoring of the cooling and freezing rates and the
freezing curve for individual units and storage of the
unit’s freezing record allows for this information to
be reviewed at any time as well as upon release of the
CB unit for transplantation and analysis of the impact
of this data on unit quality and transplant outcome.
Analysis of the freezing profiles for over 40,000 banked
units in a total of 16 BioArchive freezers has revealed
impressive similarity of the slope of the curves and very
small numbers of ‘‘deviations,’’ demonstrating that the
CB freezing process can be standardized and is highly
reproducible. TheNCBP has introduced the review of
the CB unit’s freezing profile as a criterion for accept-
ing the unit into the inventory, and investigation of the
impact of the freezing profile of CB units from differ-
ent freezers and different banks should be a priority for
the CB field.
Precryopreservation testing of the cellular content
of a CB unit includes the TNC, mononuclear cell,
CD341 cell counts, and CFUs. The CFU assay is
the only assay used in routine banking practice that de-
termines the potency of the hematopoietic progeni-
tors, and the NCBP has demonstrated that the CFU
dose correlates with the speed of clinical engraftment
[24]. However, the traditional CFU assay is limited
by technical challenges, given that the evaluation of
growth and enumeration of colonies is performed
manually by light microscopy and is thus is time con-
suming, subjective, and very difficult to standardize
among different laboratories. The NCBP have devel-
oped and implemented a computer-based system that
automates colony staining with precise concentrations
of 3-[4,5-dimethylthiazol-2yl]-2,5-diphenyltetrazo-
lium bromide (MTT) and high-resolution digital im-
aging. This methodology allows testing of large
numbers of samples in a ‘‘high throughput’’ assay.
To date, more than 3000 CB units have been tested
in duplicate (average: 30 CB samples/day) in the
160 Biol Blood Marrow Transplant 15:154-161, 2009J. N. Barker et al.NCBP CFU Laboratory. Importantly, 60 culture
dishes can be processed in\2 hours, and digital imag-
ing and storage permits a more precise analysis, classi-
fication, and enumeration of different colonies and
assay standardization. Furthermore, colony images
can be subsequently reviewed and prior to the release
of a CB unit for transplantation. Utilization of this
strategy for the evaluation of CFU growth from an at-
tached segment of NCBP CB units is now underway.
Results of the CFU assays as well as CD341 cell viabil-
ity from thawed CB segments serve as a critical quality
control measure for the entire cryopreservation pro-
cess. Therefore, all NCBP units processed after Au-
gust 2006 released for transplantation now have
CFU assays performed prior to cryopreservation and
prior to release from the attached segment. Analyses
comparing these assays precryopreservation and post-
thaw, and correlation of the segment CFU assays and
patient engraftment are underway.ImprovingTransplantAccess by aHighlyDiverse
Donor Inventory and Rapid Access to CB Grafts
Despite over 300,000 CB units stored worldwide
[25], patients of ethnic minorities remain underserved.
Equal access to transplantation for patients of all eth-
nic backgrounds has been an important goal of theNa-
tional Cord Blood Inventory and diversity of donors is
a hallmark of CB banking. The NCBP’s current
searchable inventory of approximately 45,000 units in-
cludes 9% Asian, 16% African-American, and 14%
multirace donors. Notably, over 40% of the CB units
released for transplantation are for patients of ethnic
and racial minorities. Specifically, 19% of NCBP
CBT recipients have been of African-American de-
scent, and over 60% of those patients have received
units from donors of the same race. Asian patients rep-
resent 5% of the total CBT recipients and of those
over 50% have received units from Asian donors.
The results of matching the donor and recipient race
are more striking now than in the past, reflecting the
increase in the inventory and access to large numbers
of donors in the same ethnic groups.
One of the main advantages of CB grafts is their
availability ‘‘upon demand.’’ Therefore, the goal of
the NCBP is to permit rapid access to units. All infec-
tious disease and hemoglobinopathy testing as well as
donor evaluations are completed before the CB unit
becomes available for search. Thus, the only barrier
to unit release is the final step of confirmation of unit
identity by HLA typing of an attached segment. The
NCBP HLA Laboratory is able to process requests
for confirmatory HLA typing within 24-48 hours, in
contrast to the 5-7 days routinely required by other
laboratories. Therefore, the interval from search to ac-
tual transplant can be significantly shortened. Al-
though the median time from the submission ofa patient search to the shipment of a CB unit is 66
days (data for the period 10/2006-04/2008, n 5 748
units shipped), a significant proportion of units are
shipped within a few days: 123 units (16% during
this period) were shipped in\30 days from search ini-
tiation. In real emergencies CB units have been re-
leased to TCs within 24 hours. Therefore, CB
becomes the ‘‘graft of choice’’ in urgent situations.
Patients were offered CBT if allogeneic transplant
was indicated and no suitably HLAmatched related or
URD were available in the required time period. No-
tably, 42% of patients were of non-North Western
European ancestry with 50% of patients being non-
European. In addition, the 4 patients of North-West-
ern European ancestry had proven or potential 9-10 of
10 HLA-A, B, C, DRB1, or DQ allele matched URD
but received CB because of transplant urgency (n5 1)
or patient/MD preference (n 5 3). CB grafts were 4-6
of 6 HLA-matched at A, B antigens and DRB1 alleles.ACKNOWLEDGMENTS
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